Clinical trial
A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas
NCT01555242 is registered in ClinicalTrials.gov with Omnitura Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas
- Lead sponsor
- Omnitura Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2012
- Completion date
- January 31, 2014
- Enrollment
- 22 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.